ReviewJournal of clinical medicine2025
Hypercoagulability in Tuberculosis: Pathophysiological Mechanisms, Associated Risks, and Advances in Management-A Narrative Review.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- The Clinical and Hematological Markers of Pulmonary Embolism: Multicenter Retrospective Study in Mongolia.Hematology reports · 2026Article
- QuantiFERON-TB Gold Plus Conversion Among Healthcare Workers: A Retrospective Cohort Study on Occupational and Metabolic Factors.Healthcare (Basel, Switzerland) · 2026Article
- Pulmonary Embolism Complicating Active Pulmonary Tuberculosis: Two Case Reports of Tuberculosis-Associated Hypercoagulability.Diagnostics (Basel, Switzerland) · 2026Article
- Does Tuberculosis Leave a Thromboinflammatory Memory After Cure? A Narrative Review with a Conceptual Framework on Hypercoagulability, Cellular Reservoirs, and Extracellular Vesicle Signaling.International journal of molecular sciences · 2026Review
- Immune endotypes in tuberculosis: Keys to decoding disease complexity.Journal of internal medicine · 2026Review
- Multidrug-Resistant Tuberculosis in Central and Eastern Europe: Implementation and Maturity of Whole-Genome Sequencing for Surveillance.Diseases (Basel, Switzerland) · 2026Review
- Platelet-leucocyte interactions drive MMP-mediated tissue damage in tuberculosis.PLoS pathogens · 2026Article
- Non-Small-Cell Lung Cancer: From Histopathological Classification to Precision Oncology-A Narrative Review.Journal of clinical medicine · 2026Review
- Clinical epidemiology and risk prediction of unsuccessful treatment outcomes in pulmonary tuberculosis with diabetes mellitus.BMC medicine · 2026Article
- Hypercoagulability in Pulmonary Tuberculosis: Reduced Protein C and Free Protein S Predict Pulmonary Embolism-Evidence from a Prospective Romanian Cohort.Journal of clinical medicine · 2026Article
- Cardiac autonomic function in bronchiectasis and age and gender-matched healthy participants: case-control study.Scientific reports · 2026Article
- Insulin Resistance and Inflammation.International journal of molecular sciences · 2026Review
- Beyond the Lungs: Cardiovascular Risk in COPD Patients with a History of Tuberculosis-A Narrative Review.Journal of clinical medicine · 2026Review
- Systemic Inflammation in Retinal Vein Occlusion and Its Role in Clinical Outcomes of Secondary Macular Edema.Journal of clinical medicine · 2026Article
- Endothelial, cytokine, and Th1/cellular host biomarkers discriminate complicated osteoarticular tuberculosis: a prospective single-center cohort study with ROC analysis.Frontiers in cellular and infection microbiology · 2026Observational
- Risk factors for thrombosis in tuberculosis patients admitted to a tuberculosis-dedicated intensive care unit: a retrospective cohort study.Frontiers in medicine · 2026Article
- A case description of multisystem tuberculosis complicated with diabetes mellitus and pulmonary embolism.Quantitative imaging in medicine and surgery · 2026Article
- Assessment of some hematological and inflammatory parameters among patients with active pulmonary tuberculosis in Ibb governorate, Yemen.BMC infectious diseases · 2025Article
- Lung epithelial injury impairs early host immune responses to Mycobacterium tuberculosis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- History of Pulmonary Tuberculosis Accelerates Early Onset and Severity of COPD: Evidence from a Multicenter Study in Romania.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) induces a hypercoagulable state characterized by systemic inflammation, endothelial dysfunction, and alterations in the coagulation and fibrinolytic pathways. This review explores the pathophysiological mechanisms underlying hypercoagulability in TB, including increased pro-inflammatory cytokine release, endothelial damage, platelet activation, and reduced anticoagulant and fibrinolytic activity. These factors contribute to an elevated risk of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), which complicate TB prognosis and treatment. The potential role of adjunctive anti-inflammatory therapies, such as vitamin D, NSAIDs, corticosteroids, and anti-platelet agents, is highlighted as a strategy to mitigate systemic inflammation and reduce thrombotic risks in patients with TB. The challenges of anticoagulation therapy, particularly in managing the interactions between anti-TB medications and traditional anticoagulants, are discussed, along with the potential of novel oral anticoagulants (NOAs) as alternatives. We also address therapy of hypercoagulability in TB within resource-limited settings which requires low-cost diagnostics, accessible anticoagulation options, adjunctive therapies, and preventive strategies integrated into existing healthcare systems. Effective risk stratification and individualized management strategies are vital for reducing the morbidity and mortality associated with thrombotic complications in TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.